AARON THRIFT to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications AARON THRIFT has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
1.274
-
Authors' reply to: Statin use and risk of liver cancer. Int J Cancer. 2019 10 01; 145(7):2009.
Score: 0.376
-
Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality. Clin Gastroenterol Hepatol. 2019 09; 17(10):2117-2125.e3.
Score: 0.365
-
The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A Retrospective Cohort Study of United States Veterans. Am J Gastroenterol. 2018 09; 113(9):1310.
Score: 0.351
-
Statin use and risk of liver cancer: Evidence from two population-based studies. Int J Cancer. 2020 03 01; 146(5):1250-1260.
Score: 0.094
-
Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Aliment Pharmacol Ther. 2018 08; 48(4):469-477.
Score: 0.088